Xenon Pharmaceuticals (NASDAQ:XENE) experienced unusually high options trading activity, with traders acquiring 4,063 put options, a 2,362% increase over the average, signaling bearish sentiment. This comes despite the stock having a consensus “Buy” rating and trading higher on the reported day. The article also notes significant insider selling, including a large transaction by the CEO, alongside institutional inflows and various analyst ratings.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals (NASDAQ:XENE) experienced unusually high options trading activity, with traders acquiring 4,063 put options, a 2,362% increase over the average, signaling bearish sentiment. This comes despite the stock having a consensus “Buy” rating and trading higher on the reported day. The article also notes significant insider selling, including a large transaction by the CEO, alongside institutional inflows and various analyst ratings.